AR025779A1 - Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion. - Google Patents
Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion.Info
- Publication number
- AR025779A1 AR025779A1 ARP000105032A ARP000105032A AR025779A1 AR 025779 A1 AR025779 A1 AR 025779A1 AR P000105032 A ARP000105032 A AR P000105032A AR P000105032 A ARP000105032 A AR P000105032A AR 025779 A1 AR025779 A1 AR 025779A1
- Authority
- AR
- Argentina
- Prior art keywords
- eletriptan
- crystalline polymorphic
- pharmaceutical composition
- composition containing
- preparation procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El presente trata de una forma polimorfica cristalina de un compuesto de formula (1) caracterizada por un diagrama de difraccion de rayos X en polvo,obtenido al utilizar la radiacion K-alfa1 del cobre (lambda = 0,15046 nm), que presenta picosprincip ales a 9,28, 10,38, 11,37, 12,40, 16,84, 17,46, 17,53,17,78, 17,98, 19,48, 20,70, 21,29, 21,45, 22,21, 22,64, 23,08, 25,20 y 25,79. Se refiere también a procedimientos para la preparacion de dicha forma, acomposiciones farmacéuticas quecontienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonistade receptores 5-HT1, tales como, por ejemplo, la migrana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922963.5A GB9922963D0 (en) | 1999-09-28 | 1999-09-28 | Polymorphic salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025779A1 true AR025779A1 (es) | 2002-12-11 |
Family
ID=10861767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105032A AR025779A1 (es) | 1999-09-28 | 2000-09-26 | Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion. |
Country Status (50)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
| US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
| GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
| US8771733B2 (en) * | 2004-12-03 | 2014-07-08 | Merck Sharp & Dohme Corp. | Pharmaceutical composition containing an anti-nucleating agent |
| WO2007047447A2 (en) * | 2005-10-17 | 2007-04-26 | Neurotherapeutics Pharma, Inc. | Diuretic-like compound analogs useful for regulation of central nervous system disorders |
| KR100814109B1 (ko) * | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
| TWI394753B (zh) * | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體 |
| WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
| IN2012DN03377A (es) | 2009-10-26 | 2015-10-23 | Merck Sharp & Dohme |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| DE10299004I2 (de) * | 1990-10-15 | 2006-03-16 | Pfizer | Indolderivate |
| US5578612A (en) | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| US5998462A (en) * | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| EA002174B1 (ru) * | 1997-07-03 | 2002-02-28 | Пфайзер Инк. | Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин |
-
1999
- 1999-09-28 GB GBGB9922963.5A patent/GB9922963D0/en not_active Ceased
-
2000
- 2000-07-25 TW TW089114850A patent/TWI265926B/zh not_active IP Right Cessation
- 2000-07-28 PA PA20008498901A patent/PA8498901A1/es unknown
- 2000-08-10 CO CO00059853A patent/CO5180567A1/es not_active Application Discontinuation
- 2000-09-14 DZ DZ003254A patent/DZ3254A1/fr active
- 2000-09-14 MX MXPA02003311A patent/MXPA02003311A/es active IP Right Grant
- 2000-09-14 DK DK00954864T patent/DK1233960T3/da active
- 2000-09-14 JP JP2001526529A patent/JP3795395B2/ja not_active Expired - Fee Related
- 2000-09-14 EP EP00954864A patent/EP1233960B1/en not_active Expired - Lifetime
- 2000-09-14 SI SI200030165T patent/SI1233960T1/xx unknown
- 2000-09-14 IL IL14715400A patent/IL147154A/xx not_active IP Right Cessation
- 2000-09-14 SK SK398-2002A patent/SK3982002A3/sk unknown
- 2000-09-14 AU AU67213/00A patent/AU779580B2/en not_active Ceased
- 2000-09-14 GE GE4699A patent/GEP20043365B/en unknown
- 2000-09-14 EE EEP200200171A patent/EE200200171A/xx unknown
- 2000-09-14 TR TR2002/00804T patent/TR200200804T2/xx unknown
- 2000-09-14 HU HU0202821A patent/HUP0202821A3/hu unknown
- 2000-09-14 PT PT00954864T patent/PT1233960E/pt unknown
- 2000-09-14 CN CNB00810798XA patent/CN1155594C/zh not_active Expired - Fee Related
- 2000-09-14 PL PL00354960A patent/PL354960A1/xx not_active IP Right Cessation
- 2000-09-14 BR BR0014272-7A patent/BR0014272A/pt not_active Application Discontinuation
- 2000-09-14 YU YU2602A patent/YU2602A/sh unknown
- 2000-09-14 WO PCT/IB2000/001305 patent/WO2001023377A2/en active IP Right Grant
- 2000-09-14 AT AT00954864T patent/ATE246185T1/de not_active IP Right Cessation
- 2000-09-14 KR KR10-2002-7003963A patent/KR100479897B1/ko not_active IP Right Cessation
- 2000-09-14 UA UA2002032432A patent/UA72272C2/uk unknown
- 2000-09-14 OA OA1200200077A patent/OA12024A/en unknown
- 2000-09-14 AP APAP/P/2002/002457A patent/AP2004A/en active
- 2000-09-14 ES ES00954864T patent/ES2200911T3/es not_active Expired - Lifetime
- 2000-09-14 CZ CZ2002971A patent/CZ2002971A3/cs unknown
- 2000-09-14 DE DE60004262T patent/DE60004262T2/de not_active Expired - Lifetime
- 2000-09-14 EA EA200200302A patent/EA004510B1/ru not_active IP Right Cessation
- 2000-09-14 NZ NZ516093A patent/NZ516093A/xx unknown
- 2000-09-14 CA CA002379572A patent/CA2379572C/en not_active Expired - Fee Related
- 2000-09-19 US US09/664,946 patent/US6369094B1/en not_active Expired - Fee Related
- 2000-09-25 EG EG20001216A patent/EG24143A/xx active
- 2000-09-26 GT GT200000159A patent/GT200000159A/es unknown
- 2000-09-26 MY MYPI20004476A patent/MY121170A/en unknown
- 2000-09-26 AR ARP000105032A patent/AR025779A1/es active IP Right Grant
- 2000-09-26 PE PE2000001010A patent/PE20010662A1/es not_active Application Discontinuation
- 2000-09-27 TN TNTNSN00187A patent/TNSN00187A1/fr unknown
-
2001
- 2001-12-10 CU CU20010293A patent/CU23200A3/es not_active IP Right Cessation
- 2001-12-19 BG BG106240A patent/BG65161B1/bg unknown
-
2002
- 2002-01-08 IS IS6223A patent/IS2162B/is unknown
- 2002-01-24 CR CR6561A patent/CR6561A/es not_active Application Discontinuation
- 2002-03-15 MA MA26556A patent/MA26821A1/fr unknown
- 2002-03-26 NO NO20021525A patent/NO321936B1/no not_active IP Right Cessation
- 2002-03-26 ZA ZA200202406A patent/ZA200202406B/en unknown
- 2002-03-28 HR HR20020270A patent/HRP20020270B1/xx not_active IP Right Cessation
-
2003
- 2003-01-07 HK HK03100144.2A patent/HK1048628B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR025779A1 (es) | Forma polimorfica cristalina de eletriptan, composicion farmaceutica que la contiene, uso de la forma y procedimiento de preparacion. | |
| ES2614934T3 (es) | Nueva forma cristalina III de agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| RU2471782C2 (ru) | Твердые формы, содержащие (+)-2-[1-(3-этокси-4-метоксифенил)-2-метилсульфонилэтил]-4-ацетиламиноизоиндолин-1, 3-дион, их композиции и применение | |
| ECSP044975A (es) | Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, metodos de preparación y composiciones que los contienen | |
| JP2018203751A (ja) | エストロゲン受容体モジュレーターおよびその用途 | |
| AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| IL110494A0 (en) | Perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them | |
| GEP20084467B (en) | Gamma crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it | |
| UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
| CA2410311A1 (en) | Barbituric acid analogs as therapeutic agents | |
| SI1902026T1 (sl) | Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja | |
| PE20060372A1 (es) | Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol | |
| RS50044B (sr) | Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka | |
| AR029571A1 (es) | Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
| CL2008003811A1 (es) | Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor. | |
| US20140171646A1 (en) | Amorphous forms of palonosetron hydrochloride | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| UA84896C2 (ru) | Производные гидронопола как агонисты человеческих рецепторов orl1 | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| RU2007130150A (ru) | Новая солевая форма агониста дофамина | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |